MetaCap

4D Molecular Therapeutics (FDMT) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

4D Molecular Therapeutics (FDMT) has outperformed Valneva (VALN) over the past year, losing 5.6% versus a loss of 40.1%. Over five years, FDMT leads with a -53.6% price change compared with -91.3% for VALN. 4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $490.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FDMT-5.63%VALN-40.14%
+60%+5%-50%
Nov 21, 20251 yearNov 20, 2026
FDMT-55.64%VALN-89.45%
+53%-23%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FDMT versus VALN key metrics
MetricFDMTVALN
Share price$10.23$5.16
Market cap$576.76M$490.86M
1-day change-4.57%-3.82%
YTD return+36.40%-41.50%
1-year return-5.63%-40.14%
5-year return-53.61%-91.34%
Forward P/E—4.34
EPS (TTM)$-2.70$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.21M—
Revenue growth (YoY)+230194.59%—
Net income (latest FY)$-140.11M—
Operating margin-187.24%—
Net margin-164.43%—
52-week high$16.93$12.18
52-week low$6.96$4.75
Distance from 52-week high-39.57%-57.64%
Analyst consensusstrong_buynone
Avg. price target upside+174.58%+137.98%
Average volume967.00K23.10K
Shares outstanding56.38M95.13M
Employees196620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FDMT has outperformed VALN by 34.5 percentage points over the past year.

About 4D Molecular Therapeutics

FDMT stock →

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

FDMT vs VALN FAQ

Which is bigger, 4D Molecular Therapeutics or Valneva?

4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $490.86M for Valneva (VALN).

Which stock has performed better over the past year, FDMT or VALN?

FDMT returned -5.63% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.

Are 4D Molecular Therapeutics and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons